Person: ERSOY, YELIZ EMINE
4 results
Search Results
Now showing 1 - 4 of 4
Publication Metadata only p53 expression and relationship with MDM2 amplification in breast carcinomas(2016-04-01) Buyukpinarbasili, NUR; Gucin, ZÜHAL; Ersoy, YELİZ EMİNE; ILBAK, Ayca; Kadioglu, HÜSEYİN; Muslumanoglu, Mahmut; BÜYÜKPINARBAŞILI, NUR; GÜCİN, ZÜHAL; ERSOY, YELIZ EMINE; KADIOĞLU, HÜSEYİNCarcinoma of the breast, like other malignancies, is a genetic disease with multiple genetic events leading to the malignant phenotype. p53 mutations are the most common genetic events in human cancer. Inactivation of p53 can be a result of mutation in gene sequence. One of the main structures that regulate p53 stabilization is MDM2. It suppresses p53 transcriptional activation by recognizing transactivation domain of p53. The loss of MDM2 function on p53 regulation results in deprivation of p53 tumor suppressor ability. Single nucleotide polymorphisms (SNP309 T->G exchange) or MDM2 amplification has been proposed to play a role in this issue. In the present study, our aim is to analyze p53 and MDM2 status and investigate their interactions in human sporadic breast carcinoma. The study groups were separated according to their molecular classifications. In each group, histologic type of the tumor, conventional prognostic parameters, p53, and MDM2 interactions were compared statistically. Tumors are divided into 4 subtypes due to estrogen and progesterone receptor status, HER-2, and Ki-67 proliferation index results. According to this classification, 23 cases are in the luminal A, 32 cases are in the luminal B, 15 cases are in the HER-2 positive, and 22 cases are in the triple-negative group, with a total of 92 cases. p53 expression is low in luminal breast carcinomas than HER-2 and triple-negative subtypes. MDM2 amplification frequency was found to be 5.4% in total. MDM2 gene amplification does not have a significant role in breast carcinogenesis, but other possible mechanisms may play a role in its inactivation. (C) 2016 Elsevier Inc. All rights reserved.Publication Metadata only Comment on: Actinomycotic Infection of the Abdominal Wall Mimicking a Malignant Neoplasm by Yi et al.(2012-12-01) Kadioglu, HÜSEYİN; Ersoy, YELİZ EMİNE; Bozkurt, SÜLEYMAN; Memmi, NAİM; CIPE, Gokhan; Gucin, ZÜHAL; MUSLUMANOGLU, Mahmut; KADIOĞLU, HÜSEYİN; ERSOY, YELIZ EMINE; BOZKURT, SÜLEYMAN; MEMMİ, NAİM; GÜCİN, ZÜHALPublication Open Access Intraoperative palpation of sentinel lymph nodes can accurately predict axilla in early breast cancer(2019-01-01) Ozkurt, Enver; Yardimci, ERKAN; Tukenmez, Mustafa; Ersoy, YELİZ EMİNE; Yilmaz, Ravza; Cabioglu, Neslihan; Karanlik, Hasan; Kulle, Cemil Burak; Malya, FATMA ÜMİT; Onder, Semen; Gucin, ZÜHAL; Igci, Abdullah; Ozmen, Vahit; Dinccag, Ahmet Sait; Muslumanoglu, Mahmut; YARDIMCI, ERKAN; ERSOY, YELIZ EMINE; MALYA, FATMA ÜMİT; GÜCİN, ZÜHALRecent randomized trials have shown that completion axillary lymph node dissection (ALND) is not required in all patients with a positive sentinel lymph node (SLN) who will receive radiation therapy. Although routine intraoperative pathologic assessment (IPA) becomes unnecessary and less indicated by breast surgeons in the United States and some European countries, it is still widely used all around the world. In this prospective study, the feasibility of intraoperative nodal palpation (INP) as opposed to IPA of the SLN has been analyzed. Between March 2014 and June 2015, 305 patients with clinical T1-2/N0 breast cancer from two different breast clinics (cohort A; [n = 225] and cohort B; [n = 80]) who underwent any breast surgery with sentinel lymph node biopsy (SLNB) were included in this study. Surgeons evaluated the SLNs by manual palpation before sending for IPA, and findings compared with the final pathology. The positive predictive values (PPV) of INP and IPA were 81.8% and 97.9%, respectively, whereas the negative predictive values (NPV) of INP and IPA were 83% and 92.4%. The accuracies of INP and IPA were 82.6% and 94.1%, respectively. If patients with SLNB including micrometastasis were also considered in the final pathologic assessment (FPA) (-) group that would not require a further axillary dissection, the revised NPV of INP and FPA were found to be 92.6% and 98.1%, respectively. The revised accuracy of INP also found to be increase to 86.9%. Our study, which is the only prospective one about palpation of dissected SLNs in the literature, suggests that INP can help to identify patients who do not need ALND, which encourages omitting IPA in cT1-2 N0 breast cancer.Publication Open Access Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest(2015-08-01) Gucin, ZÜHAL; GECER, Melin Ozgun; Buyukpinarbasili, NUR; SONMEZ, Cavide; Ersoy, YELİZ EMİNE; MUSLUMANOGLU, Mahmut; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; ERSOY, YELIZ EMINEObjective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy. The goal of this study was to highlight the significance of PR− breast carcinomas. Methods: Therefore, 146 breast carcinomas comprising 87 ER+/PR+ and 59 ER+/PR− carcinomas were examined. These two groups were compared in terms of age; tumor type; tumor size; histologic grade; presence of an in situ component; lymphovascular and perineural invasion; and ER, PR, c-Erb B2, Ki-67, and epidermal growth factor receptor (EGFR) status. Results: While the number of metastatic lymph node and related pN2+pN3 tumors were found to be significantly higher in the ER+/ PR− group, the differences with respect to the tumor size, metastatic lymph node size, and frequency of lymphovascular invasion were nearly significant. Conclusion: ER+/PR− tumors have an unfavorable prognosis and show a clinical behavior closer to triple negative ones, although classified as luminal tumors. Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy.